Xavier Vidal
Impact in
- Geriatrics and Gerontology top 1%
- Pharmaceutical Practices and Patient Outcomes
- Hepatology top 2%
- Hepatitis C virus research
Papers in
-
- Pharmaceutical Practices and Patient Outcomes 11
- Pharmacology 10
- Drug-Induced Hepatotoxicity and Protection 6
- Co-authors
- Joan‐Ramon Laporte (38 shared papers)Luisa Ibáñez (32 shared papers)Elena Ballarín (17 shared papers)Lourdes Vendrell (8 shared papers)E. Pérez (11 shared papers)Vı́ctor Moreno (2 shared papers)Xavier Carné (2 shared papers)Antònia Agustí (25 shared papers)
In The Last Decade
Xavier Vidal
124 papers receiving 5.0k citations
Xavier Vidal's Hit Papers
Peers
Comparison fields: 5 of 106
- Geriatrics and Gerontology 225
- Hepatology 539
- Toxicology 209
- Pharmacology 225
- Pharmacology 327
Countries citing papers authored by Xavier Vidal
This map shows the geographic impact of Xavier Vidal's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xavier Vidal with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xavier Vidal more than expected).
Fields of papers citing papers by Xavier Vidal
This network shows the impact of papers produced by Xavier Vidal. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xavier Vidal. The network helps show where Xavier Vidal may publish in the future.
Co-authors
The 25 scholars most cited alongside Xavier Vidal, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 129 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Randomized Trial of Posaconazole and Benznidazole for Chronic Chagas' Disease Hit paper breakdown → | 2014 | 512 |
| 2 | 1990 | 321 | |
| 3 | 1991 | 277 | |
| 4 | Rivaroxaban Versus Vitamin K Antagonist in Antiphospholipid Syndrome Hit paper breakdown → | 2019 | 258 |
| 5 | 1991 | 242 | |
| 6 | 2004 | 212 | |
| 7 | 2005 | 163 | |
| 8 | 2011 | 156 | |
| 9 | 2008 | 148 | |
| 10 | 2004 | 135 | |
| 11 | 2010 | 118 | |
| 12 | 2005 | 111 | |
| 13 | 2002 | 110 | |
| 14 | 2008 | 90 | |
| 15 | 2016 | 89 | |
| 16 | 2016 | 84 | |
| 17 | 2000 | 81 | |
| 18 | 1990 | 80 | |
| 19 | 2015 | 79 | |
| 20 | 2007 | 74 |
About Xavier Vidal
Xavier Vidal is a scholar working on Geriatrics and Gerontology, Pharmacology, Toxicology, Cardiology and Cardiovascular Medicine and Infectious Diseases, having authored 129 papers that have together received 5.3k indexed citations. Recurring topics across this work include Pharmaceutical Practices and Patient Outcomes (11 papers), Pharmacovigilance and Adverse Drug Reactions (8 papers), Drug-Induced Hepatotoxicity and Protection (6 papers), Atrial Fibrillation Management and Outcomes (5 papers), Blood disorders and treatments (5 papers), Hip and Femur Fractures (5 papers), Systemic Lupus Erythematosus Research (5 papers) and Gastrointestinal Bleeding Diagnosis and Treatment (4 papers). The work is most often cited by research in Geriatrics and Gerontology (225 citations), Hepatology (539 citations), Toxicology (209 citations), Pharmacology (225 citations) and Pharmacology (327 citations). Xavier Vidal has collaborated with scholars based in Spain, Italy and Peru. Frequent co-authors include Joan‐Ramon Laporte, Luisa Ibáñez, Elena Ballarín, Lourdes Vendrell, E. Pérez, Vı́ctor Moreno, Xavier Carné, Antònia Agustí, Dolors Capellà and Eva Montané. Their work appears in journals such as European Journal of Clinical Pharmacology, Frontiers in Pharmacology, Drug Safety, British Journal of Clinical Pharmacology and Alimentary Pharmacology & Therapeutics.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.